Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called anaplastic large cell lymphoma (ALCL), which is a rare form of non-Hodgkin lymphoma. Specifically, the study is looking at cases that are ALK-positive, meaning they have a particular genetic feature that can affect how the cancer grows. The trial is aimed at children and adolescents who have been newly diagnosed with this condition and are considered to have a standard risk level.

The treatment being tested in this study is a medication called Vinblastine Sulfate. This medication is given as an injection into a vein and is known to be a type of drug that interferes with the growth of cancer cells. The purpose of the study is to see if using Vinblastine Sulfate alone for a period of 24 months can effectively treat at least 75% of patients with this type of lymphoma.

Participants in the study will receive Vinblastine Sulfate and will be monitored over time to see how well the treatment works. The study will track the health of participants for at least three years to understand the long-term effects of the treatment. The goal is to determine the likelihood of patients remaining free from cancer-related events, such as the cancer returning or worsening, over a three-year period. This information will help doctors understand if Vinblastine Sulfate is a good treatment option for this type of cancer in young patients.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial screening and consent

    Upon joining the study, the first step involves confirming eligibility. This includes being diagnosed with ALK-positive anaplastic large cell lymphoma (ALCL) and being under 18 years of age.

    Consent from parents or legal guardians is required, along with the child's agreement if they are capable. This consent covers participation in the study and the handling of personal data.

  2. Step 2

    Pre-treatment procedure

    Before starting the main treatment, a procedure called intrathecal triple therapy is administered. This involves the use of three medications: Methotrexate, Cytarabine, and Prednisolone (or Hydrocortisone).

    This procedure is done to prepare the body for the main treatment.

  3. Step 3

    Vinblastine treatment

    The main treatment involves the administration of Vinblastine sulfate. This medication is given through a vein, a method known as intravenous use.

    The treatment with Vinblastine is planned to last for 24 months. The specific dosage and frequency will be determined by the medical team based on individual needs.

  4. Step 4

    Follow-up period

    After completing the treatment, a follow-up period of at least 3 years is expected. This is to monitor health and ensure the effectiveness of the treatment.

    During this time, regular check-ups and assessments will be conducted to track progress and address any concerns.

Who can join the trial?

7 criteria

  • Must be diagnosed with ALK-positive anaplastic large cell lymphoma (ALCL) and classified as standard risk. This means the disease is in a specific stage: Stage I not completely removed by surgery, or Stage II or III, and must be MDD negative (no minimal disease detected).
  • Must be younger than 18 years old.
  • Parents or legal guardians must give their informed consent for the child to participate in the study. If the child is able to understand, they must also agree to participate.
  • Must participate in the national or study group's reference pathology, which involves specific medical evaluations.
  • Must be able to be followed up for at least 3 years after joining the study.
  • If sexually active, must use a highly effective method of birth control.
  • Must receive one dose of a specific treatment called intrathecal triple therapy with Methotrexate, Cytarabine, and Prednisolone (or Hydrocortisone) before starting the main treatment in the study. This involves delivering medication directly into the spinal fluid.

Who cannot join the trial?

5 criteria

  • Patients who do not have ALK-positive anaplastic large cell lymphoma (ALCL) cannot participate. ALCL is a type of cancer that affects the lymphatic system, which is part of the immune system.
  • Patients who are not considered to be at standard risk for this condition cannot participate. Standard risk refers to the usual level of risk associated with the disease.
  • Patients who are not within the specified age range cannot participate. The age range for this study is not specified here, but it is important for eligibility.
  • Patients who are not able to follow the treatment plan of Vinblastine-monotherapy for 24 months cannot participate. Vinblastine is a medication used to treat certain types of cancer, and monotherapy means using this medication alone without combining it with other treatments.
  • Patients who are not able to provide informed consent or who are part of a vulnerable population may not be eligible. Vulnerable populations include groups who may have limited ability to make informed decisions about their participation in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Vinblastine is a medication used in this clinical trial to treat children and adolescents with a specific type of cancer called ALK-positive anaplastic large cell lymphoma (ALCL). This medication works by stopping the growth of cancer cells, which helps to shrink the tumors. In this study, Vinblastine is being tested to see if it can effectively cure at least 75% of patients when used alone over a period of 24 months. The goal is to determine if this treatment can be a successful option for patients with standard risk ALCL.

What is already known about the treatment

Vinblastine – Vinblastine is administered as an injection directly into a vein, a method known as intravenous administration. It is currently being studied in clinical trials for its effectiveness in treating children and adolescents with a type of cancer called standard risk ALK-positive anaplastic large cell lymphoma (ALCL). The main goal of using Vinblastine in this context is to cure at least 75% of patients with this condition when used as a single therapy over a period of 24 months. At the molecular level, Vinblastine works by interfering with the growth of cancer cells, preventing them from dividing and multiplying. It is classified as a chemotherapy drug, specifically a type of medication known as a vinca alkaloid.

Investigated diseases

Anaplastic Large Cell Lymphoma, ALK-Positive – Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma characterized by the presence of large, abnormal lymphocytes. The ALK-positive variant is identified by the expression of the anaplastic lymphoma kinase (ALK) protein. This disease often begins with painless swelling of lymph nodes, which may be accompanied by fever, weight loss, and night sweats. As it progresses, it can affect various organs, leading to symptoms depending on the areas involved. The disease can spread to other parts of the body, including the skin, bones, and soft tissues. The progression can vary, with some cases remaining localized while others become more widespread.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2022-501454-11-00Protocol codeALCL-VBLEstimated enrolment137 patientsSponsorGPOH gGmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).